[Baricitinib in COVID-19 patients]

Luxardo R, Ciapponi A, Colaci C, Alfie V, García Martí S, Bardach A, Augustovski F, Alcaraz A, Pichon-Riviere A
Record ID 32018002335
Original Title: Baricitinib en pacientes con COVID-19
Authors' recomendations: Moderate-quality evidence suggests that baricitinib associated to the standard of care reduces mortality and the need of mechanical ventilation; additionally it does not increase the incidence of serious adverse events. Most clinical practice guidelines from the United States recommend associating baricitinib to the standard of care in adult hospitalized patients experiencing a rapid progression to oxygen requirement. Most United States health funders cover baricitinib based on the indications approved by the regulatory agencies. The rest of the funders consulted do not mention this technology. One economic evaluation from the United States suggests that baricitinib associated with the standard of care was more effective and less costly than the standard of care alone. No local economic evaluations on the cost-effectiveness of baricitinib have been found for this indication.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • COVID-19
  • SARS-CoV-2
  • Coronavirus Infections
  • Azetidines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Antiviral Agents
  • Janus Kinase Inhibitors
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.